Adding to the ever-growing list of newly discovered bacterial immune systems, we have characterized the mechanisms of an ...

ArrakisTx was formed to create RNA-intercepting drugs to fight cancer. Despite some promising data, CEO @michael_gilman says it will shift targets.

In all living organisms, DNA contains the code that defines cellular structures and functions. An enzyme called RNA ...

Pharma giant GSK is buying into Rgenta Therapeutics’ mission to develop a pipeline of oral RNA-targeting small molecules. | ...

By deducing the possible ancient forms of a bacterial enzyme, OIST scientists have resurrected one of its ancestral versions, ...

"Dune"-inspired Arrakis Therapeutics has tested its spice—an RNA-targeting small molecule—in a mouse model of myotonic ...

4′-Fluorouridine works against RNA-dependent RNA polymerase, an enzyme that helps viruses assemble RNA. The compound has a ...

Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules ...

LMU researchers have investigated how cationic polymers organize on a molecular level when transporting RNA drugs.

The United States Food and Drug Administration has just approved the first-ever clinical trial that uses CRISPR-Cas13 RNA ...

Dominique Verhelle is co-founder and CEO of the Brighton-based company NextRNA Therapeutics, which uses long non-coding RNA ...

Researchers investigate the influence of Mettl1 on energy metabolism and the maturation of heart cells after birth.